Pay in 4 interest-free payments of $6.44 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
The evidence reality There is no robust, high-quality human outcomes literature showing that adding AOD-9604 to semaglutide or tirzepatide produces clinically meaningful additional fat loss beyond what GLP-1/GIP therapy already achieves
In addition, tirzepatide affects certain chemicals in the brain which in turn decreases food intake, increases energy expenditure, and prevents ectopic fat deposition (abnormal fat accumulation in body parts that normally contains small amounts of fat)
Maintaining weight loss after GLP1 treatment requires more than medication alone
225 Im S-A, Cortes J, Cescon DW, Yusof MM, Iwata H, Masuda N, Takano T, Huang C-S, Chung C-F, Tsugawa K, et al
Not for human consumption, therapeutic application, or veterinary use
The primary pathway of GLP-1 activity is thought to be via neuropods (i.e., synapses between the enteroendocrine cells and afferent branches of the vagus nerve) which transmit signals to certain nuclei in the brainstem
